Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 60 Breast 49 Thoracic 40 Gynecologic 29 Genitourinary 29 Tumor-Agnostic 21 CNS 21 Dermatologic 17 Head & Neck 16 Other hematologic neoplasm 14 Lymphoid 14 Sarcoma 12 Myeloid 9 Plasma cell 6 Other solid neoplasm 6 Endocrine 3 Classical hematology 2 Other neoplasm 1 Other 1 NET 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 28 Magnetic Resonance Spectroscopy 15 Everolimus 10 pembrolizumab 9 Specimen Handling 9 cabozantinib 7 Nivolumab 7 Lutetium-177 6 surufatinib 5 lenvatinib 5 Octreotide 5 177Lu-octreotide, DOTA(0)-Tyr(3)- 5 lanreotide 4 gallium Ga 68 dotatate 4 amino-acid, glucose, and electrolyte solution 4 X-Rays 4 Lutetium 4 Ipilimumab 4 Injections 4 Fluorodeoxyglucose F18 4 Capecitabine 4 olaparib 3 copper dotatate CU-64 3 atezolizumab 3 Temozolomide 3 Cyclophosphamide 3 Carboplatin 3 pasireotide 2 fludarabine phosphate 2 fludarabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Blood Specimen Collection × NET × 1 year × Clear all

NCT06430021 2026-05-22

PRO-NEM1

Centre Hospitalier Universitaire Dijon

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡